Table 2.
Correlation analysis between expression of VISTA protein and expression of other immune checkpoints in breast cancer patients.
| Clinicopathological characteristic | Group | Number | VISTA | P-value | |
|---|---|---|---|---|---|
| Pos (n, %) | Neg (n, %) | ||||
| Pos | 38 (30.89%) | 17 (44.74%) | 21 (55.26%) | ||
| PD-1 (n = 123) | 0.038* | ||||
| Neg | 85 (69.11%) | 22 (25.88%) | 63 (74.12%) | ||
| Pos | 31 (23.31%) | 4 (12.90%) | 27 (87.10%) | ||
| PD-L1 (n = 133) | 0.204 | ||||
| Neg | 102 (76.69%) | 24 (23.53%) | 78 (76.47%) | ||
| Pos | 119 (93.70%) | 39 (32.77%) | 80 (67.23%) | ||
| TIGIT (n = 127) | N/A | ||||
| Neg | 8 (6.30%) | 0 (0.00%) | 8 (100.00%) | ||
| Pos | 75 (59.06%) | 32 (42.67%) | 43 (57.33%) | ||
| TIM3 (n = 127) | 0.052 | ||||
| Neg | 52 (40.94%) | 7 (13.46%) | 45 (86.54%) | ||
| Pos | 7 (5.51%) | 2 (28.57%) | 5 (71.43%) | ||
| LAG3 (n = 127) | 0.900 | ||||
| Neg | 120 (94.49%) | 37 (30.83%) | 83 (69.17%) | ||
VISTA, V-domain Ig suppressor of T cell activation; Pos, positive; Neg, negative.
In bold: *p < 0.05, indicates a statistically significant difference.